EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
4.580
+0.015 (0.33%)
At close: Sep 4, 2026, 4:00 PM EDT
4.570
-0.010 (-0.22%)
After-hours: Sep 4, 2026, 7:46 PM EDT
EyePoint Revenue
EyePoint had revenue of $507.00K in the quarter ending June 30, 2026, a decrease of -90.49%. This brings the company's revenue in the last twelve months to $2.79M, down -94.63% year-over-year. In the year 2025, EyePoint had annual revenue of $31.37M, down -27.50%.
Revenue (ttm)
$2.79M
Revenue Growth
-94.63%
P/S Ratio
141.63
Revenue / Employee
$13,028
Employees
214
Market Cap
394.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.37M | -11.90M | -27.50% |
| Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
| Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
| Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
| Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
| Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
| Dec 31, 2019 | 20.37M | 15.79M | 345.53% |
| Dec 31, 2018 | 4.57M | 1.61M | 54.37% |
| Jun 30, 2018 | 2.96M | -4.58M | -60.72% |
| Jun 30, 2017 | 7.54M | 5.92M | 365.37% |
| Jun 30, 2016 | 1.62M | -24.95M | -93.90% |
| Jun 30, 2015 | 26.57M | 23.09M | 664.90% |
| Jun 30, 2014 | 3.47M | 1.33M | 62.06% |
| Jun 30, 2013 | 2.14M | -1.38M | -39.22% |
| Jun 30, 2012 | 3.53M | -1.44M | -28.98% |
| Jun 30, 2011 | 4.97M | -18.09M | -78.46% |
| Jun 30, 2010 | 23.05M | 10.89M | 89.55% |
| Jun 30, 2009 | 12.16M | 8.69M | 249.88% |
| Jun 30, 2008 | 3.48M | 1.69M | 94.73% |
| Jun 30, 2007 | 1.79M | 749.00K | 72.30% |
| Jun 30, 2006 | 1.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 65.26M |
| vTv Therapeutics | 36.84M |
| Zentalis Pharmaceuticals | 26.87M |
| X4 Pharmaceuticals | 15.85M |
| Opus Genetics | 9.86M |
| Palisade Bio | 500.00K |
EYPT News
- 5 days ago - EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting - GlobeNewsWire
- 5 days ago - EyePoint downgraded to Hold from Buy at TD Cowen - TheFly
- 10 days ago - EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law - Business Wire
- 19 days ago - EyePoint price target lowered to $20 from $43 at Jones - TheFly
- 20 days ago - EyePoint downgraded to Neutral from Buy at Chardan - TheFly
- 20 days ago - EyePoint downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 20 days ago - EyePoint price target lowered to $17 from $35 at Citi - TheFly
- 20 days ago - EyePoint downgraded to Sector Perform from Outperform at RBC Capital - TheFly